Inogen, Inc. (NASDAQ:INGN) Shares Sold by Fred Alger Management LLC

Fred Alger Management LLC decreased its stake in Inogen, Inc. (NASDAQ:INGNFree Report) by 2.7% in the 3rd quarter, HoldingsChannel reports. The institutional investor owned 712,842 shares of the medical technology company’s stock after selling 19,477 shares during the period. Fred Alger Management LLC’s holdings in Inogen were worth $6,915,000 as of its most recent SEC filing.

A number of other hedge funds have also recently modified their holdings of INGN. Connor Clark & Lunn Investment Management Ltd. lifted its position in Inogen by 312.5% in the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 174,625 shares of the medical technology company’s stock valued at $1,694,000 after acquiring an additional 132,287 shares during the last quarter. Vanguard Group Inc. increased its position in shares of Inogen by 4.9% during the first quarter. Vanguard Group Inc. now owns 1,424,026 shares of the medical technology company’s stock worth $11,492,000 after purchasing an additional 65,954 shares in the last quarter. B. Riley Wealth Advisors Inc. purchased a new stake in shares of Inogen in the 2nd quarter valued at about $457,000. Divisadero Street Capital Management LP boosted its position in shares of Inogen by 682.3% in the 2nd quarter. Divisadero Street Capital Management LP now owns 2,346,766 shares of the medical technology company’s stock valued at $19,079,000 after purchasing an additional 2,046,766 shares during the period. Finally, Sanctuary Advisors LLC acquired a new position in Inogen during the second quarter worth approximately $651,000. 89.94% of the stock is owned by hedge funds and other institutional investors.

Inogen Stock Up 0.8 %

Shares of INGN stock opened at $9.71 on Friday. The stock’s 50-day moving average price is $9.52 and its 200 day moving average price is $9.65. The stock has a market capitalization of $231.27 million, a PE ratio of -4.32 and a beta of 1.04. Inogen, Inc. has a 52-week low of $4.93 and a 52-week high of $13.33.

Analyst Upgrades and Downgrades

Several research firms have recently weighed in on INGN. StockNews.com downgraded Inogen from a “buy” rating to a “hold” rating in a report on Thursday, November 21st. Needham & Company LLC reiterated a “hold” rating on shares of Inogen in a research note on Friday, November 8th.

Check Out Our Latest Stock Report on Inogen

Inogen Profile

(Free Report)

Inogen, Inc, a medical technology company, develops, manufactures, and markets portable oxygen concentrators to patients, physicians and other clinicians, and third-party payors in the United States and internationally. Its oxygen concentrators are used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions.

Further Reading

Want to see what other hedge funds are holding INGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Inogen, Inc. (NASDAQ:INGNFree Report).

Institutional Ownership by Quarter for Inogen (NASDAQ:INGN)

Receive News & Ratings for Inogen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inogen and related companies with MarketBeat.com's FREE daily email newsletter.